Randi Isaacs

Dr. Randi Isaacs is a veteran hematologist and oncologist focused on discovery and development of novel therapeutic approaches in oncology, specializing in immunotherapy, biologic agents, and cell therapies for the treatment of solid tumors and hematologic malignancies. She has devoted her career to bringing new therapeutics to cancer patients to improve clinical outcomes and has made contributions to several successfully registered drugs.

Dr. Isaacs has more than 20 years’ experience in clinical and translational oncology drug development, most recently as the Executive Director and Clinical Site Head of Translational Clinical Oncology at the Novartis Institutes for Biomedical Research (NIBR). She previously held executive leadership roles in oncology and clinical development at Merck, Schering Plough, and Sandoz, where she led projects in all phases of clinical research and supported business development and licensing.

Prior to transitioning to biopharma, Dr. Isaacs held various academic appointments including Assistant Professor of Medicine in the Division of Hematology/Oncology at the State University of New York Health Sciences Center and Clinical Assistant Professor of Hematology/Oncology at the University of Medicine and Dentistry of New Jersey.

Dr. Isaacs earned her B.A. in Chemistry from Wellesley College and holds an M.D. from Dartmouth Medical School. She completed her residency and postdoctoral training at the University of California San Francisco and the Memorial Sloan-Kettering Cancer Center respectively.